Clinical research

Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial

EuroIntervention 2014;10:204-211. DOI: 10.4244/EIJV10I2A34

Victor Legrand1, MD; Thomas Cuisset², MD; Patrick Chenu³, MD; Mathy Vrolix4, MD; Christophe Martinez1, MD; Joseph Dens4, MD; Olivier Gach1, MD; Jean Boland5, MD; Marc J. Claeys6, MD; Julien Magne1, PhD; Emanuele Barbato², MD; William Wijns²*, MD

1. CHU de Liège, Liège, Belgium; 2. Cardiovascular Center Aalst OLV-Clinic, Aalst, Belgium; 3. CHU Mont Godinne, Godinne, Belgium; 4. St Jan Ziekenhuis Genk, Genk, Belgium; 5. CHR Citadelle Liège, Liège, Belgium; 6. UZ Antwerpen, Antwerp, Belgium

Aims: The Stent Thrombosis In Belgium (STIB) trial aimed to determine whether assessing platelet reactivity (PR) in patients with stable coronary artery disease undergoing elective percut

Forgot your password?

No account yet? Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

biochemical markerscoronary artery diseasepharmacologystable anginastent thrombosis

Share on Facebook Share on Twitter Share on Linkedin